Oral Cavity Squamous Cell Carcinoma — Variants & evidence

Oral Cavity Squamous Cell Carcinoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

3 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
GAS6 EXPRESSION1
(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID1657 128 patients with oral squamous cell carcinoma (OSCC) and 145 normal control subjects were evaluated for the concentration of GAS6 in their plasma serum. OSCC patients were found to be associated with… (full text at CIViC) PMID 26207647 · Jiang et al., 2015 · Open in CIViC	civic
LGR5 delta51
(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID9621 In a clinical trial including 78 patients, expression of delta5 is significantly associated with decreased OS (p = 0.02) and DFS (p = 0.01) by multivariate analysis. PMID 30770730 · Rot et al., 2019 · Open in CIViC	civic
TP53 DNA Binding Domain Mutation1
(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID641 Oral squamous cell carcinoma patients with TP53 mutations in the DNA binding domain (L2, L3 and the LSH motif) have significantly reduced cumulative survival when compared to patients with TP53 mutati… (full text at CIViC) PMID 12509970 · Yamazaki et al., 2003 · Open in CIViC	civic

Data updated 23 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.